scholarly journals Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome

2018 ◽  
Vol 43 (5) ◽  
pp. 752-756 ◽  
Author(s):  
Qin Xiang Ng ◽  
Alex Yu Sen Soh ◽  
Donovan Yutong Lim ◽  
Wee‐Song Yeo
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Option ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals A sustained hypothalamic–pituitary–adrenal axis response to acute psychosocial stress in irritable bowel syndrome

2014 ◽  
Vol 44 (14) ◽  
pp. 3123-3134 ◽  
Author(s):  
P. J. Kennedy ◽  
J. F. Cryan ◽  
E. M. M. Quigley ◽  
T. G. Dinan ◽  
G. Clarke
Keyword(s):  
Irritable Bowel Syndrome ◽  
Hpa Axis ◽  
Psychosocial Stress ◽  
Trier Social Stress Test ◽  
Hypothalamic Pituitary Adrenal ◽  
Gi Symptoms ◽  
Irritable Bowel ◽  
Acute Psychosocial Stress ◽  
Novel Therapeutic ◽  
The Way

BackgroundDespite stress being considered a key factor in the pathophysiology of the functional gastrointestinal (GI) disorder irritable bowel syndrome (IBS), there is a paucity of information regarding the ability of IBS patients to respond to acute experimental stress. Insights into the stress response in IBS could open the way to novel therapeutic interventions. To this end, we assessed the response of a range of physiological and psychological parameters to the Trier Social Stress Test (TSST) in IBS.MethodThirteen female patients with IBS and 15 healthy female age-matched control participants underwent a single exposure to the TSST. Salivary cortisol, salivary C-reactive protein (CRP), skin conductance level (SCL), GI symptoms, mood and self-reported stress were measured pre- and post-exposure to the TSST.ResultsThe hypothalamic–pituitary–adrenal (HPA) axis response to the TSST was sustained in IBS, as shown by a greater total cortisol output throughout (p = 0.035) and higher cortisol levels measured by an area under the curve with respect to ground (AUCG) analysis (p = 0.044). In IBS patients, GI symptoms increased significantly during the recovery period following exposure to the TSST (p = 0.045). Salivary CRP and SCL activity showed significant changes in relation to stress but with no differential effect between experimental groups.ConclusionsPatients with IBS exhibit sustained HPA axis activity, and an increase in problematic GI symptoms in response to acute experimental psychosocial stress. These data pave the way for future interventional studies aimed at identifying novel therapeutic approaches to modulate the HPA axis and GI symptom response to acute psychosocial stress in IBS.

scholarly journals Effect of Multispecies Probiotic Supplementation on Irritable Bowel Syndrome

2019 ◽  
pp. 1-9
Author(s):  
Saeed Yazdani Ashtiani ◽  
Mersad Amery
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Therapeutic Option ◽  
Intervention Group ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Probiotic Supplementation ◽  
Irritable Bowel

Background: Irritable bowel syndrome (IBS) is a common, chronic and sometimes disabling functional disorder of the gastrointestinal system and its treatment remains as health problem. Thus the aim of this study was to evaluate the Effect of multispecies probiotic supplementation, as a novel and Controversial therapeutic method on Irritable bowel syndrome. Materials and Methods: In this randomized double blind Placebo-controlled clinical trial, 60 patients with IBS were enrolled. The patients were divided randomly into two groups. Patients in intervention group received two 500 mg probiotic capsules (Familact®) and in control group, received two 500 mg placebo capsules daily for 30 consecutive days. The symptoms and quality of life were measured and compared at the beginning and just after the end of study for each case. Results: Results showed the mean score of Abdominal pain after 1 month of treatment in the probiotic group was significantly lower than the control group (1.76 ± 2.04 vs. 2.88 ± 2.25, P=0.049, respectively). While, other symptoms and quality of life did not change significantly (P>0.05). Furthermore, defecation habit and global symptoms improvement was similar after intervention in both groups and we did not observe significant differences in these items (P>0.05). Conclusion: The results of this study showed the beneficial effects of multispecies probiotic supplementation in controlling IBS patients’ abdominal pain. thus it can be prescribed as a therapeutic option in addition to standard therapy and significantly lead to better control of this symptom in the short term.

Novel therapeutic approaches in the treatment of irritable bowel syndrome

2007 ◽  
Vol 148 (20) ◽  
pp. 923-928 ◽  
Author(s):  
István Pregun ◽  
László Herszényi ◽  
Márk Juhász ◽  
Pál Miheller ◽  
Zsolt Tulassay
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Approaches ◽  
Irritable Bowel ◽  
Novel Therapeutic

Az irritábilis bél szindróma (IBS) kezelése a változatos tünetek, a társuló neuropszichiátriai kórképek miatt nem könnyű feladat. Bár számos, különböző támadáspontú szert alkalmazunk a betegség kezelésére, a mai napig kevés olyan gyógyszer van, amelynek hatékonyságáról, biztonságosságáról és tolerabilitásáról egyértelmű bizonyítékok állnak rendelkezésre. Az IBS multikauzális jellegéből adódóan a visceralis hiperszenzitivitással, a motilitással, az agy-bél tengely szabályozási zavaraival kapcsolatos kutatások eredményei, a folyamatokban központi szerepet játszó neurotranszmitterek, ezek receptorainak megismerése teremtette meg az új kezelési lehetőségek alapját. Bár napjainkban néhány gyógyszert (alosetron, tegaserod) már törzskönyveztek egyes országokban IBS-ben, az új készítményekkel kapcsolatban még több, nagy betegszámú vizsgálatra van szükség.

scholarly journals Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome

2007 ◽  
Vol 104 (3) ◽  
pp. 263-273 ◽  
Author(s):  
Takuya Hirata ◽  
Yoshihiro Keto ◽  
Toshiyuki Funatsu ◽  
Shinobu Akuzawa ◽  
Masao Sasamata
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Pharmacological Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

2009 ◽  
Vol 133 (5) ◽  
pp. 281-291
Author(s):  
Takuya Hirata ◽  
Toshiyuki Funatsu ◽  
Yoshihiro Keto ◽  
Shinobu Akuzawa ◽  
Hiraku Akiho ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Agent ◽  
Clinical Profile ◽  
Irritable Bowel ◽  
Novel Therapeutic

scholarly journals TREATMENT OF PATIENT WITH IRRITABLE BOWEL SYNDROME WITH DIET MODIFICATION – A CASE REPORT

2020 ◽  
Vol 4 (9) ◽  
Author(s):  
Malayala Tejaswini ◽  
Tarun Ponugoti ◽  
Anthireddy Sahithreddy
Keyword(s):  
Irritable Bowel Syndrome ◽  
Social Life ◽  
Lifestyle Modification ◽  
Therapeutic Option ◽  
Developed Countries ◽  
Sensory Function ◽  
Older Individuals ◽  
High Fiber ◽  
Diet Modification ◽  
Irritable Bowel

Irritable Bowel Syndrome (IBS) is characterized by chronic relapsing abdominal pain, bloating and changes in bowel habits. Despite very real symptoms, the gross and microscopy evaluation is normal in most IBS patients Due to difficulty in diagnosis, incidence is not clearly known. Prevalence in developed countries is between 5% and 10 percent. Throughout the world about 10-20 percent of adults and adolescents have symptoms consistent with IBS.IBS is a disorder that effect all ages although most patients have their first symptom before age 45.Older individuals have a lover reporting frequency. Women are diagnosed with IBS 2-3 times as often as men and makeup 80 percent of population with severe IBS. IBS is a bio-psychosocial disorder in which 3 major mechanicals interact: psychosocial factors, altered motility and heightened sensory function of intestine. Due to multifactorial etiology there is no single therapeutic option available with satisfactory efficiency. Therefore, patients with high frequency of symptoms express high levels of frustration with their frequent hospital visits, decreased work & social life and food sensitivity. If treatment is carried out to improve symptoms, some people can control their symptoms by managing diet, lifestyle and stress. Others need medication and counselling. In our case the patient wasn’t satisfied with the pharmacotherapy alone. He used diet modification and lifestyle modification as a main treatment strategy. Satisfactory results were observed with such changes. Keywords: IBS, psychosocial, bio-psychosocial, lifestyle modification, diet modification, low FODMAP diet, high fiber diet, yoga, stress

Sign in / Sign up

Export Citation Format

Share Document